Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Aeris and DAG lead Adamas' $40mm Series D financing

Executive Summary

Adamas Pharmaceuticals (combination treatments for neurological and infectious diseases) sold $40mm in stock through its Series D round led by Aeris Capital, which contributes a new board member, and DAG Ventures. Returning shareholders Mohr Davidow Ventures, Northgate Capital, and Ontario Teachers Pension also joined.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies